Topical tazarotene has not been studied during breastfeeding. Some experts feel it should not be used on a large surface area (perhaps greater than 20% of body surface area) while nursing because of possible absorption.[1] Others recommend that it not be used during breastfeeding because of its suspected mutagenic properties.[2] If tazarotene is used, ensure that the infant's skin does not come into direct contact with the areas of maternal skin that have been treated and the infant does not ingest the product from the mother's skin.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Yaghi M, McMullan P, Truong TM, et al. Safety of dermatologic medications in pregnancy and lactation: An Update - Part II: Lactation. J Am Acad Dermatol 2024;91:651-68. [PubMed: 38280680]
2.
Gottlieb AB, Ryan C, Murase JE. Clinical considerations for the management of psoriasis in women. Int J Womens Dermatol 2019;5:141-50. [PMC free article: PMC6637092] [PubMed: 31360745]
Substance Identification
Substance Name
Tazarotene
CAS Registry Number
118292-40-3
Drug Class
Breast Feeding
Lactation
Milk, Human
Dermatologic Agents
Keratolytic Agents
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
